NY-AQARA
23.3.2023 09:01:30 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, announces the wide availability of the Company’s first smart video doorbell, the G4, on global markets. This 1080p doorbell features wide compatibility with third-party smart home platforms such as Apple Home, Alexa and Google Home, and it is equipped with on-device AI to enable local facial recognition alerts and automation. Together with the Company’s indoor cameras, the video doorbell G4 helps users keep an eye on their homes, families and visitors anytime, anywhere. The device is now available on Aqara’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as via selective Aqara retailers worldwide1.
Similar to Aqara’s Camera Hub G3, the Aqara Smart Video Doorbell G4 features AI-based facial recognition, which is executed locally on device for faster response and privacy protection. Moreover, facial recognition of the doorbell can be used as an automation trigger, allowing users to set up customized home automation for different families and visitors. For example, the welcome home scene will be activated when the G4 recognizes a family member coming home. Or in the case that it detects the postman, the doorbell will play a pre-recorded message. When connected to other Aqara devices, the G4 doorbell can also be a strong addition to the Aqara Home alert system as it not only monitors the activities around the front porch but also lets out a loud siren in case of home intrusion and other emergencies.
Apart from the Aqara ecosystem, the G4 doorbell also supports major third-party smart home platforms including Apple Home, Amazon Alexa and Google Home. This device is one of the few battery-powered video doorbells on the market that support Apple’s HomeKit Secure Video as well as the local streaming to Amazon and Google smart displays. Moreover, Aqara anticipates adding the support of the new Matter standard to the G4 via a future OTA (over the air) update2.
With two color variants, Shadow Gray and Black, the video doorbell G4 is designed to fit into most home environments. It supports both wireless and wired installation and can use a pack of 6 AA batteries that lasts about 4 months3. The doorbell offers adjustable sensitivity, configurable motion detection and even a power saving mode for users who live in a high traffic area to extend the battery life. Alternatively, users can opt to wire the G4 doorbell to an AC/DC transformer for 24/7 recording4, and use the battery pack as a back-up power source. Additionally, the G4’s chime repeater, which is equipped with a 95 dB speaker, houses a Type-C port, and allows more flexibility for users to place the chime repeater indoors.
Users of the Video Doorbell G4 can store video footage locally or on the cloud via iCloud or Aqara platform5. Aqara offers a subscription-free cloud storage of up to 7 days of critical event clips such as motion detection, facial recognition, doorbell ring and tamper alerts. Users can also choose to save video footage locally using a microSD card (up to 512 GB)6, which is housed in the indoor chime repeater. Finally, videos can also be stored via SMB NAS for added flexibility and security7.
For more details of the G4 video doorbell, please visit our website.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
- Matter support is not available by the time of launch.
- Based on assumption of 35 device wake-ups and one 6-second event video recording per day. The actual battery life may vary, depending on multiple factors including device usage, battery capacity, ambient temperature, etc.
- A 12-24V AC or 8-24V DC transformer is required. Both a wired installation and the use of a microSD card are required for 24/7 recording.
- iCloud or other supported cloud storage is not included, and should be controlled separately via the respecting app.
- The microSD card is not included.
- SMB NAS support may be unavailable by the time of product launch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom